社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
patrickLai
IP属地:未知
+关注
帖子 · 36
帖子 · 36
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
patrickLai
patrickLai
·
2021-12-28
Good
Will Hey Dude Help Crocs Reach $5 Billion in Sales by 2026?<blockquote>嘿,伙计,到2026年,Crocs的销售额会达到50亿美元吗?</blockquote>
Crocs made its largest acquisition to date last week when it inked a deal to acquire the privately-o
Will Hey Dude Help Crocs Reach $5 Billion in Sales by 2026?<blockquote>嘿,伙计,到2026年,Crocs的销售额会达到50亿美元吗?</blockquote>
看
3,828
回复
评论
点赞
1
编组 21备份 2
分享
举报
patrickLai
patrickLai
·
2021-12-27
Big movement
Japan Joins Coordinated Oil Sales to Combat Rising Prices<blockquote>日本加入协调石油销售以应对价格上涨</blockquote>
(Bloomberg) -- Japan kicked off the sale of oil from its strategic reserves in a bid to combat risin
Japan Joins Coordinated Oil Sales to Combat Rising Prices<blockquote>日本加入协调石油销售以应对价格上涨</blockquote>
看
3,068
回复
评论
点赞
3
编组 21备份 2
分享
举报
patrickLai
patrickLai
·
2021-12-25
Good
非常抱歉,此主贴已删除
看
4,208
回复
评论
点赞
3
编组 21备份 2
分享
举报
patrickLai
patrickLai
·
2021-12-24
Good
非常抱歉,此主贴已删除
看
4,376
回复
评论
点赞
3
编组 21备份 2
分享
举报
patrickLai
patrickLai
·
2021-12-22
Huat ah
非常抱歉,此主贴已删除
看
4,424
回复
1
点赞
5
编组 21备份 2
分享
举报
patrickLai
patrickLai
·
2021-12-19
Like like
Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir 跻身医疗保健涨幅之列,辉瑞创下十年来最佳涨势</blockquote>
The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5
Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir 跻身医疗保健涨幅之列,辉瑞创下十年来最佳涨势</blockquote>
看
2,896
回复
1
点赞
4
编组 21备份 2
分享
举报
patrickLai
patrickLai
·
2021-12-18
Yeah
Cerner Shares Surge On Reports Of $30 Billion Oracle Takeover Bid<blockquote>Cerner 股价因甲骨文 300 亿美元收购要约的报道而飙升</blockquote>
Cerner Corp. -Get Cerner Corporation Report shares surged Friday after the Wall Street Journal repor
Cerner Shares Surge On Reports Of $30 Billion Oracle Takeover Bid<blockquote>Cerner 股价因甲骨文 300 亿美元收购要约的报道而飙升</blockquote>
看
3,514
回复
1
点赞
5
编组 21备份 2
分享
举报
patrickLai
patrickLai
·
2021-12-15
Nice
非常抱歉,此主贴已删除
看
3,510
回复
2
点赞
6
编组 21备份 2
分享
举报
patrickLai
patrickLai
·
2021-12-12
Good
非常抱歉,此主贴已删除
看
3,553
回复
1
点赞
3
编组 21备份 2
分享
举报
patrickLai
patrickLai
·
2021-12-11
[Grin]
非常抱歉,此主贴已删除
看
3,599
回复
评论
点赞
3
编组 21备份 2
分享
举报
加载更多
暂无粉丝
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3585604372962377","uuid":"3585604372962377","gmtCreate":1622512789390,"gmtModify":1638170490735,"name":"patrickLai","pinyin":"patricklai","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":10,"tweetSize":36,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.02","exceedPercentage":"80.70%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":696601923,"gmtCreate":1640674012432,"gmtModify":1640674012552,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696601923","repostId":"1120855192","repostType":4,"repost":{"id":"1120855192","kind":"news","pubTimestamp":1640668339,"share":"https://www.laohunote.com/m/news/1120855192?lang=zh_CN&edition=full","pubTime":"2021-12-28 13:12","market":"us","language":"en","title":"Will Hey Dude Help Crocs Reach $5 Billion in Sales by 2026?<blockquote>嘿,伙计,到2026年,Crocs的销售额会达到50亿美元吗?</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1120855192","media":"Footwear News","summary":"Crocs made its largest acquisition to date last week when it inked a deal to acquire the privately-o","content":"<p>Crocs made its largest acquisition to date last week when it inked a deal to acquire the privately-owned footwear brand Hey Dude.</p><p><blockquote>上周,Crocs 签署了收购私营鞋类品牌 Hey Dude 的协议,完成了迄今为止最大的一笔收购。</blockquote></p><p> The deal is valued at $2.5 billion and expected to close in Q1 of 2022. While Hey Dude is privately owned, Crocs pointed out the company’s impressive growth in revenue and profits in recent years. 43% of Hey Dude’s sales are currently online and the brand projects $570 million in revenue in 2021.</p><p><blockquote>该交易价值 25 亿美元,预计将于 2022 年第一季度完成。虽然 Hey Dude 是私有的,但 Crocs 指出,该公司近年来的收入和利润增长令人印象深刻。目前,Hey Dude 43% 的销售额来自网上,该品牌预计 2021 年收入将达到 5.7 亿美元。</blockquote></p><p> Crocs is confident that Hey Dude will help contribute to its recent revenue growth and align with its previously stated goal to help Crocs achieve$5 billion in sales by 2026.Crocs plans to make Hey Dude a $1 billion brand by 2024.</p><p><blockquote>Crocs 相信 Hey Dude 将有助于促进其近期的收入增长,并符合其之前设定的目标,即帮助 Crocs 到 2026 年实现 50 亿美元的销售额。Crocs 计划到 2024 年将 Hey Dude 打造成一个价值 10 亿美元的品牌。</blockquote></p><p> While executives seemed confident in achieving these goals, investors initially appeared more hesitant. In the wake of the announcement on Thursday, shares of Crocs dropped close to 12%, suggesting concern and uneasiness.</p><p><blockquote>虽然高管们似乎对实现这些目标充满信心,但投资者最初似乎更加犹豫。周四宣布这一消息后,Crocs 股价下跌近 12%,暗示着担忧和不安。</blockquote></p><p> However, some analysts eased investor fear and projected strong results from the acquisition.</p><p><blockquote>然而,一些分析师缓解了投资者的担忧,并预计此次收购将带来强劲的业绩。</blockquote></p><p> Williams Trading analyst Sam Poser said in a recent note that despite the reactive stock drop, the deal “will prove very accretive” to Crocs. He attributed the initial stock drop to a general investor unawareness for the Hey Dude Brand, which he said has grown revenue at a 20% rate over the last few years and is still gaining momentum.</p><p><blockquote>Williams Trading 分析师 Sam Poser 在最近的一份报告中说,尽管股价被动下跌,但这笔交易 “将证明对 Crocs 非常有利”。他将最初的股价下跌归因于一般投资者对 Hey Dude 品牌缺乏了解,他表示,该品牌在过去几年中的收入增长率为 20%,并且仍在增长动力。</blockquote></p><p> “Retailers are more knowledgeable of trends than the very large majority of the investment community is,” Poser wrote. “Crocs trends remain strong, and management remains confident that sales will reach $5 billion by 2026.”</p><p><blockquote>“波瑟写道:”零售商比投资界的绝大多数人更了解趋势。“Crocs 的发展趋势依然强劲,管理层仍然有信心到 2026 年销售额将达到 50 亿美元。”</blockquote></p><p> Baird analyst Jonathan Komp also pointed out Hey Dude’s trajectory of rapid growth, highlighting how the company is estimated to have grown revenue twofold in 2021, despite supply chain issues. The brand is projected to hit $700 to $750 million in revenue in 2022.</p><p><blockquote>贝尔德分析师乔纳森-孔普(Jonathan Komp)也指出了 Hey Dude 的快速增长轨迹,强调尽管存在供应链问题,该公司预计 2021 年收入仍将翻一番。该品牌预计 2022 年收入将达到 7 亿至 7.5 亿美元。</blockquote></p><p> Crocs acquired Jibbitz, the company that makes accessories for the clogs, in 2006. Its most recent acquisition initiates the company’s transition from single-brand to multi-brand.Once under the Crocs banner, Hey Dude will still operate independently with Hey Dude founder Alessandro Rosano as strategic advisor and creative director. Former CCM Hockey CEO Rick Blackshaw has been tapped as Hey Dude’s new EVP and brand president.</p><p><blockquote>Crocs 于 2006 年收购了为木屐制造配件的公司 Jibbitz。最近的收购开启了公司从单品牌向多品牌的转型。一旦在Crocs的旗帜下,Hey Dude仍将独立运营,Hey Dude创始人Alessandro Rosano担任战略顾问和创意总监。前 CCM Hockey 首席执行官 Rick Blackshaw 已被任命为 Hey Dude 的新任执行副总裁兼品牌总裁。</blockquote></p><p> “In upcoming quarters, we are optimistic that Crocs can prove continued strong execution as the company has as a mono-brand operator, which should reinforce investor confidence in the growth outlook and support higher valuation over time,” Komp wrote.</p><p><blockquote>“Komp 写道:”在接下来的几个季度中,我们乐观地认为,Crocs 能够像公司作为单品牌运营商那样继续保持强劲的执行力,这将增强投资者对增长前景的信心,并随着时间的推移支持更高的估值。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Hey Dude Help Crocs Reach $5 Billion in Sales by 2026?<blockquote>嘿,伙计,到2026年,Crocs的销售额会达到50亿美元吗?</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Hey Dude Help Crocs Reach $5 Billion in Sales by 2026?<blockquote>嘿,伙计,到2026年,Crocs的销售额会达到50亿美元吗?</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Footwear News</strong><span class=\"h-time small\">2021-12-28 13:12</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Crocs made its largest acquisition to date last week when it inked a deal to acquire the privately-owned footwear brand Hey Dude.</p><p><blockquote>上周,Crocs 签署了收购私营鞋类品牌 Hey Dude 的协议,完成了迄今为止最大的一笔收购。</blockquote></p><p> The deal is valued at $2.5 billion and expected to close in Q1 of 2022. While Hey Dude is privately owned, Crocs pointed out the company’s impressive growth in revenue and profits in recent years. 43% of Hey Dude’s sales are currently online and the brand projects $570 million in revenue in 2021.</p><p><blockquote>该交易价值 25 亿美元,预计将于 2022 年第一季度完成。虽然 Hey Dude 是私有的,但 Crocs 指出,该公司近年来的收入和利润增长令人印象深刻。目前,Hey Dude 43% 的销售额来自网上,该品牌预计 2021 年收入将达到 5.7 亿美元。</blockquote></p><p> Crocs is confident that Hey Dude will help contribute to its recent revenue growth and align with its previously stated goal to help Crocs achieve$5 billion in sales by 2026.Crocs plans to make Hey Dude a $1 billion brand by 2024.</p><p><blockquote>Crocs 相信 Hey Dude 将有助于促进其近期的收入增长,并符合其之前设定的目标,即帮助 Crocs 到 2026 年实现 50 亿美元的销售额。Crocs 计划到 2024 年将 Hey Dude 打造成一个价值 10 亿美元的品牌。</blockquote></p><p> While executives seemed confident in achieving these goals, investors initially appeared more hesitant. In the wake of the announcement on Thursday, shares of Crocs dropped close to 12%, suggesting concern and uneasiness.</p><p><blockquote>虽然高管们似乎对实现这些目标充满信心,但投资者最初似乎更加犹豫。周四宣布这一消息后,Crocs 股价下跌近 12%,暗示着担忧和不安。</blockquote></p><p> However, some analysts eased investor fear and projected strong results from the acquisition.</p><p><blockquote>然而,一些分析师缓解了投资者的担忧,并预计此次收购将带来强劲的业绩。</blockquote></p><p> Williams Trading analyst Sam Poser said in a recent note that despite the reactive stock drop, the deal “will prove very accretive” to Crocs. He attributed the initial stock drop to a general investor unawareness for the Hey Dude Brand, which he said has grown revenue at a 20% rate over the last few years and is still gaining momentum.</p><p><blockquote>Williams Trading 分析师 Sam Poser 在最近的一份报告中说,尽管股价被动下跌,但这笔交易 “将证明对 Crocs 非常有利”。他将最初的股价下跌归因于一般投资者对 Hey Dude 品牌缺乏了解,他表示,该品牌在过去几年中的收入增长率为 20%,并且仍在增长动力。</blockquote></p><p> “Retailers are more knowledgeable of trends than the very large majority of the investment community is,” Poser wrote. “Crocs trends remain strong, and management remains confident that sales will reach $5 billion by 2026.”</p><p><blockquote>“波瑟写道:”零售商比投资界的绝大多数人更了解趋势。“Crocs 的发展趋势依然强劲,管理层仍然有信心到 2026 年销售额将达到 50 亿美元。”</blockquote></p><p> Baird analyst Jonathan Komp also pointed out Hey Dude’s trajectory of rapid growth, highlighting how the company is estimated to have grown revenue twofold in 2021, despite supply chain issues. The brand is projected to hit $700 to $750 million in revenue in 2022.</p><p><blockquote>贝尔德分析师乔纳森-孔普(Jonathan Komp)也指出了 Hey Dude 的快速增长轨迹,强调尽管存在供应链问题,该公司预计 2021 年收入仍将翻一番。该品牌预计 2022 年收入将达到 7 亿至 7.5 亿美元。</blockquote></p><p> Crocs acquired Jibbitz, the company that makes accessories for the clogs, in 2006. Its most recent acquisition initiates the company’s transition from single-brand to multi-brand.Once under the Crocs banner, Hey Dude will still operate independently with Hey Dude founder Alessandro Rosano as strategic advisor and creative director. Former CCM Hockey CEO Rick Blackshaw has been tapped as Hey Dude’s new EVP and brand president.</p><p><blockquote>Crocs 于 2006 年收购了为木屐制造配件的公司 Jibbitz。最近的收购开启了公司从单品牌向多品牌的转型。一旦在Crocs的旗帜下,Hey Dude仍将独立运营,Hey Dude创始人Alessandro Rosano担任战略顾问和创意总监。前 CCM Hockey 首席执行官 Rick Blackshaw 已被任命为 Hey Dude 的新任执行副总裁兼品牌总裁。</blockquote></p><p> “In upcoming quarters, we are optimistic that Crocs can prove continued strong execution as the company has as a mono-brand operator, which should reinforce investor confidence in the growth outlook and support higher valuation over time,” Komp wrote.</p><p><blockquote>“Komp 写道:”在接下来的几个季度中,我们乐观地认为,Crocs 能够像公司作为单品牌运营商那样继续保持强劲的执行力,这将增强投资者对增长前景的信心,并随着时间的推移支持更高的估值。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://finance.yahoo.com/news/hey-dude-help-crocs-reach-190853070.html\">Footwear News</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CROX":"卡骆驰"},"source_url":"https://finance.yahoo.com/news/hey-dude-help-crocs-reach-190853070.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120855192","content_text":"Crocs made its largest acquisition to date last week when it inked a deal to acquire the privately-owned footwear brand Hey Dude.\nThe deal is valued at $2.5 billion and expected to close in Q1 of 2022. While Hey Dude is privately owned, Crocs pointed out the company’s impressive growth in revenue and profits in recent years. 43% of Hey Dude’s sales are currently online and the brand projects $570 million in revenue in 2021.\nCrocs is confident that Hey Dude will help contribute to its recent revenue growth and align with its previously stated goal to help Crocs achieve$5 billion in sales by 2026.Crocs plans to make Hey Dude a $1 billion brand by 2024.\nWhile executives seemed confident in achieving these goals, investors initially appeared more hesitant. In the wake of the announcement on Thursday, shares of Crocs dropped close to 12%, suggesting concern and uneasiness.\nHowever, some analysts eased investor fear and projected strong results from the acquisition.\nWilliams Trading analyst Sam Poser said in a recent note that despite the reactive stock drop, the deal “will prove very accretive” to Crocs. He attributed the initial stock drop to a general investor unawareness for the Hey Dude Brand, which he said has grown revenue at a 20% rate over the last few years and is still gaining momentum.\n“Retailers are more knowledgeable of trends than the very large majority of the investment community is,” Poser wrote. “Crocs trends remain strong, and management remains confident that sales will reach $5 billion by 2026.”\nBaird analyst Jonathan Komp also pointed out Hey Dude’s trajectory of rapid growth, highlighting how the company is estimated to have grown revenue twofold in 2021, despite supply chain issues. The brand is projected to hit $700 to $750 million in revenue in 2022.\nCrocs acquired Jibbitz, the company that makes accessories for the clogs, in 2006. Its most recent acquisition initiates the company’s transition from single-brand to multi-brand.Once under the Crocs banner, Hey Dude will still operate independently with Hey Dude founder Alessandro Rosano as strategic advisor and creative director. Former CCM Hockey CEO Rick Blackshaw has been tapped as Hey Dude’s new EVP and brand president.\n“In upcoming quarters, we are optimistic that Crocs can prove continued strong execution as the company has as a mono-brand operator, which should reinforce investor confidence in the growth outlook and support higher valuation over time,” Komp wrote.","news_type":1,"symbols_score_info":{"CROX":0.9}},"isVote":1,"tweetType":1,"viewCount":3828,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696046575,"gmtCreate":1640584273394,"gmtModify":1640584273568,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"title":"","htmlText":"Big movement","listText":"Big movement","text":"Big movement","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696046575","repostId":"1122841396","repostType":4,"repost":{"id":"1122841396","kind":"news","pubTimestamp":1640582377,"share":"https://www.laohunote.com/m/news/1122841396?lang=zh_CN&edition=full","pubTime":"2021-12-27 13:19","market":"fut","language":"en","title":"Japan Joins Coordinated Oil Sales to Combat Rising Prices<blockquote>日本加入协调石油销售以应对价格上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122841396","media":"Bloomberg","summary":"(Bloomberg) -- Japan kicked off the sale of oil from its strategic reserves in a bid to combat risin","content":"<p><div> (Bloomberg) -- Japan kicked off the sale of oil from its strategic reserves in a bid to combat rising prices, joining an unprecedented coordinated release of crude from strategic stockpiles that’s ...</p><p><blockquote><div>(彭博社)--日本开始出售其战略储备中的石油,以应对不断上涨的油价,加入了前所未有的战略储备中协调释放原油的行列。</div></blockquote></p><p> <a href=\"https://finance.yahoo.com/news/japan-offers-oil-strategic-reserves-023254703.html\">网页链接</a> </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/japan-offers-oil-strategic-reserves-023254703.html\">网页连接</a></blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Japan Joins Coordinated Oil Sales to Combat Rising Prices<blockquote>日本加入协调石油销售以应对价格上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJapan Joins Coordinated Oil Sales to Combat Rising Prices<blockquote>日本加入协调石油销售以应对价格上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-12-27 13:19</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> (Bloomberg) -- Japan kicked off the sale of oil from its strategic reserves in a bid to combat rising prices, joining an unprecedented coordinated release of crude from strategic stockpiles that’s ...</p><p><blockquote><div>(彭博社)--日本开始出售其战略储备中的石油,以应对不断上涨的油价,加入了前所未有的战略储备中协调释放原油的行列。</div></blockquote></p><p> <a href=\"https://finance.yahoo.com/news/japan-offers-oil-strategic-reserves-023254703.html\">网页链接</a> </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/japan-offers-oil-strategic-reserves-023254703.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://finance.yahoo.com/news/japan-offers-oil-strategic-reserves-023254703.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/japan-offers-oil-strategic-reserves-023254703.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122841396","content_text":"(Bloomberg) -- Japan kicked off the sale of oil from its strategic reserves in a bid to combat rising prices, joining an unprecedented coordinated release of crude from strategic stockpiles that’s been led by the U.S.\nA government tender offered Oman crude from the strategic reserves in Shibushi for delivery between March and June, the trade ministry said in a statement. The move is part of Japan’s plans to sell oil in coordination with other consuming nations and more sales may follow, according to a ministry official, who declined to be identified because of internal policy.\nThe Biden administration started tapping the first of its pledged 50 million barrels of reserves not long after announcing the coordinated release in late November. South Korea said last week that it will start releasing crude and oil products from its strategic reserves next month, although other countries named as part of the plan -- including China and India -- have yet to act.\nThe inaugural volume offered by Japan is 100,000 kiloliters, according to a second ministry statement. The ministry plans to announce additional sales, while monitoring the energy markets, the official said.\nAt present, there are signs of weakening oil demand in Asia given the rapid spread of the omicron variant of the coronavirus. Brent crude, the global benchmark, traded slightly higher above $76 a barrel on Monday, although it’s down by about 7% since the U.S.-led plan was announced.\nTrade Minister Koichi Hagiuda said in November that Japan would conduct the release as it replaces oil in its stockpiles. While it does that regularly, the schedule has been moved up to support similar actions elsewhere, he added.","news_type":1,"symbols_score_info":{"BZmain":0.9,"CLmain":0.9}},"isVote":1,"tweetType":1,"viewCount":3068,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698257535,"gmtCreate":1640419284637,"gmtModify":1640419284792,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698257535","repostId":"2193917819","repostType":4,"isVote":1,"tweetType":1,"viewCount":4208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698143823,"gmtCreate":1640326004272,"gmtModify":1640326004425,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698143823","repostId":"1105843279","repostType":4,"isVote":1,"tweetType":1,"viewCount":4376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691165420,"gmtCreate":1640151523703,"gmtModify":1640151523844,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"title":"","htmlText":"Huat ah","listText":"Huat ah","text":"Huat ah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691165420","repostId":"1130693665","repostType":4,"isVote":1,"tweetType":1,"viewCount":4424,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693093938,"gmtCreate":1639921078798,"gmtModify":1639921078935,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"title":"","htmlText":"Like like","listText":"Like like","text":"Like like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693093938","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","kind":"news","pubTimestamp":1639884070,"share":"https://www.laohunote.com/m/news/1122414343?lang=zh_CN&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir 跻身医疗保健涨幅之列,辉瑞创下十年来最佳涨势</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p><p><blockquote>标普500的医疗保健股表现优于大盘指数中的所有其他板块,涨幅约为 2.5%,这主要得益于并购前景。<a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>科技股以及与 COVID-19 卷土重来作斗争的股票领涨,而整体指数下跌约 1.9%。</blockquote></p><p> Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p><p><blockquote>在过去一周市值超过 2B 美元且日均交易量超过 10 万股的股票中,<a href=\"https://laohu8.com/S/ARNA\">竞技场制药</a>之后上涨约 83.8%<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>同意以约 6.7B 美元的价格收购该公司,生物技术公司溢价 100%。<a href=\"https://laohu8.com/S/CERN\">塞纳</a>该公司也加入了并购驱动的涨势,本周上涨了约 20.7%,有报道称可能出价约 $30B<a href=\"https://laohu8.com/S/ORCL\">甲骨文</a>电子病历公司。</blockquote></p><p> Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p><p><blockquote>疫苗开发商,<a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a>由于投资者对该公司的 COVID-19 疫苗获得世卫组织批准表示欢迎,股价上涨了约 30.5%。当欧洲监管机构的专家小组将于下周审查该疫苗的营销授权时,这家总部位于马里兰州的生物技术公司可能会获得进一步收益。</blockquote></p><p> <a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p><p><blockquote><a href=\"https://laohu8.com/S/BHVN\">生物港制药</a>在该公司宣布在以色列批准 NURTEC ODT (rimegepant) 后,每周上涨约 25.2%,使其成为该偏头痛药物在美国以外的首次监管胜利。与此同时,Vir Biotechnology(纳斯达克股票代码:VIR)飙升约 23.7%,跻身本月第二周涨幅最大的股票之列。本周有更多数据证实了该公司与葛兰素史克公司(纽约证券交易所股票代码:GSK)合作开发的 COVID-19 疗法具有中和奥密克戎的效果。四舍五入,<a href=\"https://laohu8.com/S/ROIV\">Roivant科学</a>增加了~22.6%。</blockquote></p><p> Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p><p><blockquote>显著涨幅:<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE) 本周成为头条新闻,再次上调了 COVID-19 疫苗的销售指导,因为快速传播的奥密克戎变种凸显了加强注射的必要性。尽管周五为期六天的涨势突然结束,<a href=\"https://laohu8.com/S/NWY\">纽约</a>这家总部位于 - 的制药巨头股价上涨约 12.7%,创下自 2009 年 3 月以来的最佳单周涨幅。</blockquote></p><p> Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p><p><blockquote>在本周表现最差的公司中,两家新上市的生物技术公司Instil Bio(纳斯达克股票代码:TIL)和Exscientia(纳斯达克股票代码:EXAI)脱颖而出,尽管它们在华尔街的评级很好,但分别下跌了19.3%和约13.5%。与此同时,处方药价格比较平台运营商 GoodRx Holdings(纳斯达克股票代码:GDRX)股价下跌约 15.6%。</blockquote></p><p> Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p><p><blockquote>上周最佳表演者、<a href=\"https://laohu8.com/S/BHG\">光明健康集团</a>,暴跌约13.1%,受到唯一发布的卖出评级的影响<a href=\"https://laohu8.com/S/GS\">高盛</a>尽管这家投资银行以基本上积极的看法开始了对管理式医疗的报道。</blockquote></p><p> Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p><p><blockquote>Allogene Therapeutics(纳斯达克股票代码:ALLO)股价下跌约 12.3%,此前该公司在 ASH 上介绍了实验性 allogeneic 的 1 期数据。<a href=\"https://laohu8.com/S/00699\">车</a>T therapies 未能让投资者兴奋不已,其中包括凯西-伍德(Cathie Wood)的方舟投资管理公司(Ark Investment Management),该公司在几天后卖出了约 160 万股该生物技术公司的股票。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir 跻身医疗保健涨幅之列,辉瑞创下十年来最佳涨势</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir 跻身医疗保健涨幅之列,辉瑞创下十年来最佳涨势</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-19 11:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p><p><blockquote>标普500的医疗保健股表现优于大盘指数中的所有其他板块,涨幅约为 2.5%,这主要得益于并购前景。<a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>科技股以及与 COVID-19 卷土重来作斗争的股票领涨,而整体指数下跌约 1.9%。</blockquote></p><p> Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p><p><blockquote>在过去一周市值超过 2B 美元且日均交易量超过 10 万股的股票中,<a href=\"https://laohu8.com/S/ARNA\">竞技场制药</a>之后上涨约 83.8%<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>同意以约 6.7B 美元的价格收购该公司,生物技术公司溢价 100%。<a href=\"https://laohu8.com/S/CERN\">塞纳</a>该公司也加入了并购驱动的涨势,本周上涨了约 20.7%,有报道称可能出价约 $30B<a href=\"https://laohu8.com/S/ORCL\">甲骨文</a>电子病历公司。</blockquote></p><p> Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p><p><blockquote>疫苗开发商,<a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a>由于投资者对该公司的 COVID-19 疫苗获得世卫组织批准表示欢迎,股价上涨了约 30.5%。当欧洲监管机构的专家小组将于下周审查该疫苗的营销授权时,这家总部位于马里兰州的生物技术公司可能会获得进一步收益。</blockquote></p><p> <a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p><p><blockquote><a href=\"https://laohu8.com/S/BHVN\">生物港制药</a>在该公司宣布在以色列批准 NURTEC ODT (rimegepant) 后,每周上涨约 25.2%,使其成为该偏头痛药物在美国以外的首次监管胜利。与此同时,Vir Biotechnology(纳斯达克股票代码:VIR)飙升约 23.7%,跻身本月第二周涨幅最大的股票之列。本周有更多数据证实了该公司与葛兰素史克公司(纽约证券交易所股票代码:GSK)合作开发的 COVID-19 疗法具有中和奥密克戎的效果。四舍五入,<a href=\"https://laohu8.com/S/ROIV\">Roivant科学</a>增加了~22.6%。</blockquote></p><p> Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p><p><blockquote>显著涨幅:<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE) 本周成为头条新闻,再次上调了 COVID-19 疫苗的销售指导,因为快速传播的奥密克戎变种凸显了加强注射的必要性。尽管周五为期六天的涨势突然结束,<a href=\"https://laohu8.com/S/NWY\">纽约</a>这家总部位于 - 的制药巨头股价上涨约 12.7%,创下自 2009 年 3 月以来的最佳单周涨幅。</blockquote></p><p> Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p><p><blockquote>在本周表现最差的公司中,两家新上市的生物技术公司Instil Bio(纳斯达克股票代码:TIL)和Exscientia(纳斯达克股票代码:EXAI)脱颖而出,尽管它们在华尔街的评级很好,但分别下跌了19.3%和约13.5%。与此同时,处方药价格比较平台运营商 GoodRx Holdings(纳斯达克股票代码:GDRX)股价下跌约 15.6%。</blockquote></p><p> Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p><p><blockquote>上周最佳表演者、<a href=\"https://laohu8.com/S/BHG\">光明健康集团</a>,暴跌约13.1%,受到唯一发布的卖出评级的影响<a href=\"https://laohu8.com/S/GS\">高盛</a>尽管这家投资银行以基本上积极的看法开始了对管理式医疗的报道。</blockquote></p><p> Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p><p><blockquote>Allogene Therapeutics(纳斯达克股票代码:ALLO)股价下跌约 12.3%,此前该公司在 ASH 上介绍了实验性 allogeneic 的 1 期数据。<a href=\"https://laohu8.com/S/00699\">车</a>T therapies 未能让投资者兴奋不已,其中包括凯西-伍德(Cathie Wood)的方舟投资管理公司(Ark Investment Management),该公司在几天后卖出了约 160 万股该生物技术公司的股票。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ORCL":"甲骨文","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","PFE":"辉瑞","ARNA":"阿里那","BK4550":"红杉资本持仓","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals dominated with a ~83.8% rise after Pfizer agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle for the electronic-medical-records company.\nVaccine developer, Novavax jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1,"symbols_score_info":{"ORCL":0.9,"PFE":0.9,"ARNA":0.9,"CERN":0.9}},"isVote":1,"tweetType":1,"viewCount":2896,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699282422,"gmtCreate":1639811267512,"gmtModify":1639811267624,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"title":"","htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699282422","repostId":"1106862392","repostType":4,"repost":{"id":"1106862392","kind":"news","pubTimestamp":1639810154,"share":"https://www.laohunote.com/m/news/1106862392?lang=zh_CN&edition=full","pubTime":"2021-12-18 14:49","market":"us","language":"en","title":"Cerner Shares Surge On Reports Of $30 Billion Oracle Takeover Bid<blockquote>Cerner 股价因甲骨文 300 亿美元收购要约的报道而飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1106862392","media":"The Street","summary":"Cerner Corp. -Get Cerner Corporation Report shares surged Friday after the Wall Street Journal repor","content":"<p><a href=\"https://laohu8.com/S/CERN\">Cerner Corp.</a> -Get Cerner Corporation Report shares surged Friday after the Wall Street Journal reported that <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> -Get Oracle Corporation Report is preparing to buy the electronic medical records company in a deal worth as much as $30 billion.</p><p><blockquote><a href=\"https://laohu8.com/S/CERN\">塞纳公司。</a>-《华尔街日报》报道后,Cerner Corporation 股价周五飙升<a href=\"https://laohu8.com/S/ORCL\">甲骨文</a>-Get Oracle Corporation报道称,甲骨文公司正准备收购这家电子病历公司,交易价值高达300亿美元。</blockquote></p><p> A takeover of Cerner, the biggest designer of software used by doctors and hospitals to mange and store medical records, would not only be one of the biggest M&A deals of the year, it would also be the biggest in Oracle's corporate history -- more than 3 times the size of its $10 billion purchase of PeopleSoft in 2005 -- and a bold statement from CEO Safra Catz, who assumed sole control of the cloud and software group in 2019.</p><p><blockquote>收购 Cerner(医生和医院用来管理和存储医疗记录的最大软件设计师)不仅将是今年最大的并购交易之一,也将是甲骨文公司历史上最大的并购交易——规模是甲骨文公司 2005 年斥资 100 亿美元收购 PeopleSoft 的 3 倍多——以及首席执行官 Safra Catz 的大胆声明,他于 2019 年独家控制了这家云和软件集团。</blockquote></p><p> Cerner, which posted third quarter revenues of $1.468 billion in October, has a 25% share of the medical records market, according to SVB Leerrink.</p><p><blockquote>根据 SVB Leerrink 的数据,Cerner 在 10 月份公布的第三季度收入为 14.68 亿美元,在医疗记录市场占有 25% 的份额。</blockquote></p><p> \"We view the potential deal as a positive for CERN as it will allow the company to undergo its transition from an EHR to a healthcare platform within the cover of a far larger organization, and with the benefit of a premium takeout valuation,\" said Leerink analysts Stephanie Davis. \"We are cautious on potential pushback from Oracle shareholders creating risk to a deal announcement, as the deal would mark a transition away from the company’s core organic growth acceleration story while the check size implies likely dilution to holders.\"</p><p><blockquote>Leerink 分析师斯蒂芬妮·戴维斯 (Stephanie Davis) 表示:“我们认为这笔潜在交易对 CERN 来说是一个积极因素,因为它将使该公司能够在一个更大的组织的掩护下从 EHR 向医疗保健平台过渡,并受益于溢价估值。”“我们对甲骨文股东的潜在抵制给交易公告带来风险持谨慎态度,因为这笔交易将标志着公司偏离核心的有机增长加速故事,而支票规模则意味着股东可能会被稀释。”</blockquote></p><p> Cerner shares ended up $10.28, or 12.9%, at $89.77. Oracle shares fell $6.60, or, 6.4%, to $96.62.</p><p><blockquote>Cerner 股价收于 10.28 美元,即 12.9%,报 89.77 美元。甲骨文股价下跌 6.60 美元,跌幅 6.4%,至 96.62 美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/22804ede647ca4b70ab697475b6acc79\" tg-width=\"966\" tg-height=\"636\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Oracle shares traded at an all-time high last week, giving the cloud and software group a market value of around $290 billion, following better-than-expected second quarter earnings and a robust near-term outlook.</p><p><blockquote>甲骨文股价上周创下历史新高,这家云和软件集团的市值约为 2900 亿美元,此前第二季度盈利好于预期,近期前景强劲。</blockquote></p><p> Oracle, which earns the bulk of its revenues from its cloud services and license support unit, beat Street earnings forecasts by a dime with an adjusted second quarter bottom line of $1.12 per share.</p><p><blockquote>甲骨文的大部分收入来自其云服务和许可证支持部门,调整后的第二季度利润率为每股 1.12 美元,超出华尔街盈利预测一毛钱。</blockquote></p><p> Cloud division revenues topped $7.5 billion as companies continue to spend on hybrid work solutions in a post-pandemic world, while overall revenues grew by 6% to $10.4 billon.</p><p><blockquote>随着大流行后的世界中公司继续在混合工作解决方案上投入资金,云部门的收入突破了 75 亿美元,而总收入增长了 6%,达到 104 亿美元。</blockquote></p><p> Bookings grew at an even faster pace, rising 11% from last year's levels, giving Oracle the confidence to forecast current quarter revenues in the region of $10.7 billion to $10.9 billion, based on growth forecasts, with profits of between $1.19 and $1.23 per share.</p><p><blockquote>预订量增长速度更快,比去年增长了 11%,这让甲骨文有信心根据增长预测预测本季度收入在 107 亿至 109 亿美元之间,每股利润在 1.19 美元至 1.23 美元之间。</blockquote></p><p></p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cerner Shares Surge On Reports Of $30 Billion Oracle Takeover Bid<blockquote>Cerner 股价因甲骨文 300 亿美元收购要约的报道而飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCerner Shares Surge On Reports Of $30 Billion Oracle Takeover Bid<blockquote>Cerner 股价因甲骨文 300 亿美元收购要约的报道而飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Street</strong><span class=\"h-time small\">2021-12-18 14:49</span>\n</p>\n</h4>\n</header>\n<article>\n<p><a href=\"https://laohu8.com/S/CERN\">Cerner Corp.</a> -Get Cerner Corporation Report shares surged Friday after the Wall Street Journal reported that <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> -Get Oracle Corporation Report is preparing to buy the electronic medical records company in a deal worth as much as $30 billion.</p><p><blockquote><a href=\"https://laohu8.com/S/CERN\">塞纳公司。</a>-《华尔街日报》报道后,Cerner Corporation 股价周五飙升<a href=\"https://laohu8.com/S/ORCL\">甲骨文</a>-Get Oracle Corporation报道称,甲骨文公司正准备收购这家电子病历公司,交易价值高达300亿美元。</blockquote></p><p> A takeover of Cerner, the biggest designer of software used by doctors and hospitals to mange and store medical records, would not only be one of the biggest M&A deals of the year, it would also be the biggest in Oracle's corporate history -- more than 3 times the size of its $10 billion purchase of PeopleSoft in 2005 -- and a bold statement from CEO Safra Catz, who assumed sole control of the cloud and software group in 2019.</p><p><blockquote>收购 Cerner(医生和医院用来管理和存储医疗记录的最大软件设计师)不仅将是今年最大的并购交易之一,也将是甲骨文公司历史上最大的并购交易——规模是甲骨文公司 2005 年斥资 100 亿美元收购 PeopleSoft 的 3 倍多——以及首席执行官 Safra Catz 的大胆声明,他于 2019 年独家控制了这家云和软件集团。</blockquote></p><p> Cerner, which posted third quarter revenues of $1.468 billion in October, has a 25% share of the medical records market, according to SVB Leerrink.</p><p><blockquote>根据 SVB Leerrink 的数据,Cerner 在 10 月份公布的第三季度收入为 14.68 亿美元,在医疗记录市场占有 25% 的份额。</blockquote></p><p> \"We view the potential deal as a positive for CERN as it will allow the company to undergo its transition from an EHR to a healthcare platform within the cover of a far larger organization, and with the benefit of a premium takeout valuation,\" said Leerink analysts Stephanie Davis. \"We are cautious on potential pushback from Oracle shareholders creating risk to a deal announcement, as the deal would mark a transition away from the company’s core organic growth acceleration story while the check size implies likely dilution to holders.\"</p><p><blockquote>Leerink 分析师斯蒂芬妮·戴维斯 (Stephanie Davis) 表示:“我们认为这笔潜在交易对 CERN 来说是一个积极因素,因为它将使该公司能够在一个更大的组织的掩护下从 EHR 向医疗保健平台过渡,并受益于溢价估值。”“我们对甲骨文股东的潜在抵制给交易公告带来风险持谨慎态度,因为这笔交易将标志着公司偏离核心的有机增长加速故事,而支票规模则意味着股东可能会被稀释。”</blockquote></p><p> Cerner shares ended up $10.28, or 12.9%, at $89.77. Oracle shares fell $6.60, or, 6.4%, to $96.62.</p><p><blockquote>Cerner 股价收于 10.28 美元,即 12.9%,报 89.77 美元。甲骨文股价下跌 6.60 美元,跌幅 6.4%,至 96.62 美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/22804ede647ca4b70ab697475b6acc79\" tg-width=\"966\" tg-height=\"636\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Oracle shares traded at an all-time high last week, giving the cloud and software group a market value of around $290 billion, following better-than-expected second quarter earnings and a robust near-term outlook.</p><p><blockquote>甲骨文股价上周创下历史新高,这家云和软件集团的市值约为 2900 亿美元,此前第二季度盈利好于预期,近期前景强劲。</blockquote></p><p> Oracle, which earns the bulk of its revenues from its cloud services and license support unit, beat Street earnings forecasts by a dime with an adjusted second quarter bottom line of $1.12 per share.</p><p><blockquote>甲骨文的大部分收入来自其云服务和许可证支持部门,调整后的第二季度利润率为每股 1.12 美元,超出华尔街盈利预测一毛钱。</blockquote></p><p> Cloud division revenues topped $7.5 billion as companies continue to spend on hybrid work solutions in a post-pandemic world, while overall revenues grew by 6% to $10.4 billon.</p><p><blockquote>随着大流行后的世界中公司继续在混合工作解决方案上投入资金,云部门的收入突破了 75 亿美元,而总收入增长了 6%,达到 104 亿美元。</blockquote></p><p> Bookings grew at an even faster pace, rising 11% from last year's levels, giving Oracle the confidence to forecast current quarter revenues in the region of $10.7 billion to $10.9 billion, based on growth forecasts, with profits of between $1.19 and $1.23 per share.</p><p><blockquote>预订量增长速度更快,比去年增长了 11%,这让甲骨文有信心根据增长预测预测本季度收入在 107 亿至 109 亿美元之间,每股利润在 1.19 美元至 1.23 美元之间。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.thestreet.com/markets/cerner-shares-surge-on-reports-of-30-billion-oracle-takeover-bid\">The Street</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ORCL":"甲骨文"},"source_url":"https://www.thestreet.com/markets/cerner-shares-surge-on-reports-of-30-billion-oracle-takeover-bid","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106862392","content_text":"Cerner Corp. -Get Cerner Corporation Report shares surged Friday after the Wall Street Journal reported that Oracle -Get Oracle Corporation Report is preparing to buy the electronic medical records company in a deal worth as much as $30 billion.\nA takeover of Cerner, the biggest designer of software used by doctors and hospitals to mange and store medical records, would not only be one of the biggest M&A deals of the year, it would also be the biggest in Oracle's corporate history -- more than 3 times the size of its $10 billion purchase of PeopleSoft in 2005 -- and a bold statement from CEO Safra Catz, who assumed sole control of the cloud and software group in 2019.\nCerner, which posted third quarter revenues of $1.468 billion in October, has a 25% share of the medical records market, according to SVB Leerrink.\n\"We view the potential deal as a positive for CERN as it will allow the company to undergo its transition from an EHR to a healthcare platform within the cover of a far larger organization, and with the benefit of a premium takeout valuation,\" said Leerink analysts Stephanie Davis. \"We are cautious on potential pushback from Oracle shareholders creating risk to a deal announcement, as the deal would mark a transition away from the company’s core organic growth acceleration story while the check size implies likely dilution to holders.\"\nCerner shares ended up $10.28, or 12.9%, at $89.77. Oracle shares fell $6.60, or, 6.4%, to $96.62.\n\nOracle shares traded at an all-time high last week, giving the cloud and software group a market value of around $290 billion, following better-than-expected second quarter earnings and a robust near-term outlook.\nOracle, which earns the bulk of its revenues from its cloud services and license support unit, beat Street earnings forecasts by a dime with an adjusted second quarter bottom line of $1.12 per share.\nCloud division revenues topped $7.5 billion as companies continue to spend on hybrid work solutions in a post-pandemic world, while overall revenues grew by 6% to $10.4 billon.\nBookings grew at an even faster pace, rising 11% from last year's levels, giving Oracle the confidence to forecast current quarter revenues in the region of $10.7 billion to $10.9 billion, based on growth forecasts, with profits of between $1.19 and $1.23 per share.","news_type":1,"symbols_score_info":{"CERN":0.9,"ORCL":0.9}},"isVote":1,"tweetType":1,"viewCount":3514,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607688637,"gmtCreate":1639532977052,"gmtModify":1639533012079,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/607688637","repostId":"2191602753","repostType":4,"isVote":1,"tweetType":1,"viewCount":3510,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604088394,"gmtCreate":1639281362231,"gmtModify":1639281362356,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604088394","repostId":"2190567199","repostType":4,"isVote":1,"tweetType":1,"viewCount":3553,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605513574,"gmtCreate":1639189549315,"gmtModify":1639190159144,"author":{"id":"3585604372962377","authorId":"3585604372962377","name":"patrickLai","avatar":"https://static.tigerbbs.com/baedd77ad7c3a28da1ae2ecc8b2e88aa","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585604372962377","authorIdStr":"3585604372962377"},"themes":[],"title":"","htmlText":"[Grin] ","listText":"[Grin] ","text":"[Grin]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605513574","repostId":"2190673267","repostType":4,"isVote":1,"tweetType":1,"viewCount":3599,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"followers","isTTM":false}